Beam Therapeutics (BEAM) director receives stock options grant for 19,676 shares

Rhea-AI Filing Summary

Beam Therapeutics Inc. director Kathleen E. Walsh received a grant of stock options covering 19,676 shares of Common Stock. The options have an exercise price of $29.55 per share and expire on June 3, 2036.

According to the footnote, the option vests in full on the earlier of the first anniversary of the grant date or immediately before next year's annual stockholder meeting, as long as Walsh continues serving on the board through the vesting date. After this grant, she holds options for 19,676 shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Walsh Kathleen E

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	19,676	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 19,676 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 19,676 options Exercise price: $29.55 per share Expiration date: June 3, 2036 +2 more

5 metrics

Options granted 19,676 options Stock Option (Right to Buy) grant to director

Exercise price $29.55 per share Strike price of granted stock options

Expiration date June 3, 2036 Option term end date

Underlying shares 19,676 shares Common Stock underlying granted options

Holdings after grant 19,676 derivative securities Total stock options held following this transaction

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, vests in full, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "29.5500""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-06-03T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vests in full financial

"The option vests in full on the earlier of the first anniversary"

annual meeting of stockholders financial

"immediately prior to the date of the next year's annual meeting of stockholders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Walsh Kathleen E

(Last) (First) (Middle)

C/O BEAM THERAPEUTICS INC.,

238 MAIN STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Beam Therapeutics Inc. [ BEAM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$29.55	06/03/2026		A		19,676		(1)	06/03/2036	Common Stock	19,676	$0	19,676	D

Explanation of Responses:

1. The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.

	By: /s/ Christine Bellon, Attorney-in-fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Beam Therapeutics (BEAM) director Kathleen Walsh report on this Form 4?

Kathleen Walsh reported receiving a grant of stock options for 19,676 shares of Beam Therapeutics Common Stock. These options were awarded as compensation for her board service and are not open-market purchases or sales of shares.

What is the exercise price and term of Kathleen Walsh’s Beam (BEAM) stock options?

The granted stock options have an exercise price of $29.55 per share and an expiration date of June 3, 2036. This means Walsh can buy Beam shares at $29.55 any time after vesting until that expiration date.

How and when do Kathleen Walsh’s Beam (BEAM) stock options vest?

The options vest in full on the earlier of the first anniversary of the grant date or immediately before next year's annual stockholder meeting. Vesting requires Walsh’s continued service on Beam’s board through the applicable vesting date.

Did Kathleen Walsh buy or sell Beam Therapeutics (BEAM) stock in the market?

No market purchase or sale is reported. The Form 4 shows a compensation-related stock option grant coded as an acquisition (A), not an open-market buy or sell transaction. It reflects an award from the company’s equity program.

How many Beam (BEAM) stock options does Kathleen Walsh hold after this grant?

Following this transaction, Walsh holds stock options covering 19,676 shares of Beam Therapeutics Common Stock directly. This filing does not show additional option positions beyond this new award, and there are no derivative positions listed as remaining.